{"id":126418,"date":"2026-09-05T21:46:05","date_gmt":"2026-09-05T21:46:05","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/126418\/"},"modified":"2026-09-05T21:46:05","modified_gmt":"2026-09-05T21:46:05","slug":"roche-stock-pharma-giant-keeps-guidance-despite-third-quarter-sales-miss","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/126418\/","title":{"rendered":"Roche Stock: Pharma Giant Keeps Guidance Despite Third-Quarter Sales Miss"},"content":{"rendered":"<p>Roche (RHHBY) stock jumped Wednesday after the pharma giant reported light third-quarter sales but kept its 2024 outlook. The Swiss drugmaker pointed to newer medicines Vabysmo, Phesgo and Ocrevus for helping drive demand in the September quarter. Vabysmo is an eye disease treatment, Phesgo treats breast cancer and Ocrevus is a multiple sclerosis drug. Sales of Vabysmo and Phesgo topped\u2026<\/p>\n<p>Copyright \u00a92026 Investor&#8217;s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8<\/p>\n","protected":false},"excerpt":{"rendered":"Roche (RHHBY) stock jumped Wednesday after the pharma giant reported light third-quarter sales but kept its 2024 outlook.&hellip;\n","protected":false},"author":2,"featured_media":126419,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[23557,23558,230,134,29189],"class_list":["post-126418","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-all-news-and-stock-ideas","tag-biotech-and-pharma-stock-news","tag-earnings","tag-roche","tag-tech-earnings"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117220631270409110","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/126418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=126418"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/126418\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/126419"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=126418"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=126418"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=126418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}